Arthrotec: the evidence speaks for itself.
This article examines the most recently published scientific literature on arthritis therapy options and available mucosal-protective agents. Emphasis is placed on the risks of current nonsteroidal anti-inflammatory drug (NSAID) therapy, the options for reducing such risks, and the published information that either supports or refutes current thinking in these areas. A comprehensive evaluation is made of clinical data related to the use of Arthrotec (diclofenac/misoprostol) in the treatment of arthritis. A recent meta-analysis of the prophylaxis of NSAID-associated upper gastrointestinal complications is reviewed. The results of this meta-analysis should help to consolidate much of the current scientific literature on the safe and effective treatment of arthritis.
Morgan
D
D
McMaster University, Hamilton, Ontario, Canada.
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000175:diagnosis / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004008:Diclofenac / Q000009:adverse effects / Q000627:therapeutic use*; D004338:Drug Combinations; D019317:Evidence-Based Medicine; D006801:Humans; D016595:Misoprostol / Q000009:adverse effects / Q000627:therapeutic use*
D000894:Anti-Inflammatory Agents, Non-Steroidal; C078133:Arthrotec; D004338:Drug Combinations; D016595:Misoprostol; D004008:Diclofenac